In another set of studies, an IL-2/CD25 fusion protein with selectivity towards the high-affinity IL-2R was shown to better amplify cancer-vaccine activated CD4+ and CD8+ T cell responses compared to WT IL-2 treatment. The gene discussed is CD4; the disease is cancer.